Welcome to Markets Desk, your midday read on what's moving the needle.
A new study is putting hard numbers behind the GLP-one story, and they're striking. Middle-aged adults using these weight-loss drugs for obesity could save more than one hundred ninety two thousand dollars in lifetime medical costs, with even greater savings for those without college degrees, adding long-term fiscal weight to an already massive pharmaceutical thesis.
Shifting to biotech, Mirum Pharmaceuticals and Incyte are out with pivotal Phase two data on Zilurgisertib for Fibrodysplasia Ossificans Progressiva, a rare and devastating condition that causes bone to form in muscle tissue. Cohort one results came in strong ahead of an FDA decision, giving investors a meaningful catalyst to watch in the rare disease space.
And on the macro front, rate expectations are back in focus. With inflation risks keeping the Federal Reserve in a cautious posture, the prospect of higher interest rates is casting a shadow over crypto markets. Risk assets sensitive to the cost of capital tend to reprice quickly when the Fed leans hawkish, and digital assets are no exception.
That's the tape. Markets Desk, signing off the floor.
